Karen A Dawes's Net Worth
$30.1 Million
Estimate Recalculated Sep 12, 2024 10:36AM EST
Who is Karen A Dawes?
Karen A Dawes has an estimated net worth of $30.1 Million. This is based on reported shares across multiple companies, which include REPLIGEN CORP, GENAISSANCE PHARMACEUTICALS INC, Barinthus Biotherapeutics plc., PDL BIOPHARMA, INC., and DEPOMED INC.
SEC CIK
Karen A Dawes's CIK is 0001261506
Past Insider Trading and Trends
2021 was Karen A Dawes's most active year for acquiring shares with 13 total transactions. Karen A Dawes's most active month to acquire stocks was the month of April. 2021 was Karen A Dawes's most active year for disposing of shares, totalling 50 transactions. Karen A Dawes's most active month to dispose stocks was the month of April. 2021 saw Karen A Dawes paying a total of $636,373.02 for 74,672 shares, this is the most they've acquired in one year. In 2021 Karen A Dawes cashed out on 59,464 shares for a total of $9,405,638.85, their largest year based on trade value.
Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!
REPLIGEN CORP (RGEN) Snapshot price: $147.07
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4/A
|
—
|
0
|
—
|
—
|
0
| ||||
Form 4
| +3.47% | 2.95K |
$67.71 | $199,947.63 | 88.17K |
Jun 14
| |||
Form 4
| +0.92% | 803 |
—
|
—
| 88.17K |
May 16
| |||
Form 4
| +4.33% | 3.63K |
$117.71 | $1,265.82 | 87.37K |
Feb 27
| |||
Form 4
| +8.47% | 6.54K |
$94.75 | -$11,729.96 | 83.74K |
Aug 29
| |||
Form 4
| +1.04% | 798 |
—
|
—
| 77.2K |
May 18
| |||
Form 4
| -1.00% | -775.00 |
$227.17 | -$176,056.75 | 76.4K |
Sep 9
| |||
Form 4
| +0.84% | 644 |
—
|
—
| 77.18K |
May 26
| |||
Form 4
| -16.13% | -14.71K |
$150.51 | -$2,214,819.39 | 76.53K |
May 25
| |||
Form 4
| -9.49% | -9.57K |
$145.02 | -$1,387,286.68 | 91.25K |
Nov 10
| |||
Form 4
| -2.56% | -2.40K |
$303.94 | -$729,466.65 | 91.25K |
Nov 2
| |||
Form 4
| -0.29% | -274.00 |
$294.26 | -$80,628.12 | 93.65K |
Sep 14
| |||
Form 4
| -6.86% | -6.92K |
$161.34 | -$1,116,128.38 | 93.92K |
Sep 1
| |||
Form 4
| -16.72% | -18.88K |
$258.24 | -$4,797,234.57 | 93.92K |
Aug 17 - Aug 18
| |||
Form 4
| -3.90% | -4.58K |
$202.09 | -$926,604.97 | 112.88K |
Jul 20
| |||
Form 4/A
| +1.21% | 1.41K |
$121.71 | -$186,749.32 | 117.46K |
Jul 13
| |||
Form 4
| +3.83% | 4.45K |
$96.21 | $428,035.11 | 117.46K |
Jul 13
| |||
Form 4
| +0.52% | 604 |
—
|
—
| 116.05K |
May 13
| |||
Form 4
| +14.61% | 14.71K |
$90.04 | -$2,102.25 | 115.45K |
May 11
| |||
Form 4
| -15.66% | -18.70K |
$115.20 | -$2,154,850.73 | 100.73K |
Jun 18
| |||
Form 4
| -0.43% | -517.00 |
$139.44 | -$72,092.82 | 119.44K |
May 20
| |||
Form 4/A
| -0.73% | -878.00 |
$137.78 | -$220,448.01 | 119.96K |
May 13 - May 18
| |||
Form 4/A
| +6.90% | 7.8K |
$53.93 | -$1,209,717.12 | 120.83K |
Apr 20 - Apr 21
| |||
Form 4
| -0.73% | -878.00 |
$137.78 | -$220,448.01 | 119.96K |
May 13 - May 18
| |||
Form 4
| +6.90% | 7.8K |
$53.93 | -$1,209,717.12 | 120.83K |
Apr 20 - Apr 21
| |||
Form 4
| -3.42% | -4.00K |
$98.70 | -$394,793.45 | 113.03K |
Feb 21
| |||
Form 4
| +19.02% | 18.7K |
$41.15 | -$968.25 | 117.03K |
Jun 17
| |||
Form 4
| +1.33% | 1.29K |
—
|
—
| 98.33K |
May 15
| |||
Form 4
| +2.19% | 2.08K |
—
|
—
| 97.04K |
May 16
| |||
Form 4
|
—
|
0
|
$23.44 | -$734,336.00 | 94.96K |
May 11
| |||
Form 4
| +1.84% | 1.71K |
—
|
—
| 94.96K |
May 18
| |||
Form 4
| +23.07% | 17.48K |
$19.20 | -$216.77 | 93.24K |
Mar 21
| |||
Form 4
| +35.87% | 20K |
—
|
—
| 75.76K |
Jul 14
| |||
Form 4
| +30.45% | 13.02K |
$13.28 | $2.28 | 55.76K |
Jun 27
| |||
Form 4
| +6.22% | 2.5K |
—
|
—
| 42.75K |
May 11
| |||
Form 4
| +2.55% | 1K |
$26.70 | $26,700.00 | 40.24K |
Nov 10
| |||
Form 4
| +3.97% | 1.5K |
—
|
—
| 39.24K |
May 21
| |||
Form 4
| +11.40% | 3.86K |
—
|
—
| 37.74K |
May 15
| |||
Form 4
| +3.04% | 1K |
$7.70 | $7,699.90 | 33.88K |
Jun 21
| |||
Form 4
| +19.40% | 5.34K |
—
|
—
| 32.88K |
May 9
| |||
Form 4
| +66.90% | 11.04K |
—
|
—
| 27.54K |
May 24
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Dec 15
| |||
Form 4
| +7.12% | 10K |
$3.49 | $34,946.00 | 150.5K |
Aug 12
| |||
Form 4
| +225.00% | 4.5K |
$3.57 | $16,084.04 | 6.5K |
Jun 14
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Sep 16
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Sep 11
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Sep 12
| |||
Form 4
| +4.17% | 2K |
$3.50 | $7,000.00 | 50K |
Dec 1
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Sep 14
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Sep 15
| |||
Form 4
|
∞
| 2K |
$3.33 | $6,660.00 | 2K |
Sep 1
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
GENAISSANCE PHARMACEUTICALS INC No price found
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| -100.00% | -17.99K |
—
|
—
|
0
|
Oct 6
| |||
Form 4
| +72.97% | 7.59K |
—
|
—
| 17.99K |
Jun 30
| |||
Form 4
|
∞
| 10.4K |
—
|
—
| 10.4K |
Mar 31
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Oct 1
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Sep 30
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Barinthus Biotherapeutics plc. (BRNS) Snapshot price: $1.27
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
|
—
|
0
|
—
|
—
|
0
|
May 10
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
May 11
| |||
Form 4
|
∞
| 1.7K |
$17.00 | $28,900.00 | 1.7K |
May 4
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Apr 29
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
PDL BIOPHARMA, INC. No price found
Chairperson the Board
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| +12.50% | 250 |
$13.55 | $3,387.50 | 2.25K |
Apr 29
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Oct 4
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Sep 11
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 20
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Nov 30
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 14
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Sep 29
| |||
Form 4/A
|
—
|
0
|
—
|
—
| 2K |
May 24
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 8
| |||
Form 4
|
∞
| 2K |
$13.55 | $27,100.00 | 2K |
May 24
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Feb 17
| |||
Form 4/A
|
—
|
0
|
—
|
—
|
0
|
Jul 23
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jul 23
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 30
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Nov 24
| |||
| No matching records found | |||||||||
Assertio Therapeutics, Inc No price found
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| -15.77% | -15.83K |
$0.79 | -$12,531.03 | 84.59K |
Scheduled
|
May 8
| ||
Form 4
| -11.07% | -12.50K |
$3.18 | -$39,793.75 | 100.42K |
Scheduled
|
Jun 13
| ||
Form 4
| +168.30% | 70.83K |
—
|
—
| 112.92K |
May 7 - May 8
| |||
Form 4
| +18.53% | 6.58K |
$3.17 | -$18,374.80 | 42.09K |
Dec 3
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
May 8
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Aug 15
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
May 18
| |||
Form 4
| -5.40% | -734.00 |
$17.52 | -$12,859.68 | 12.87K |
May 12
| |||
Form 4
| -10.10% | -1.20K |
$19.00 | -$22,762.00 | 10.66K |
Dec 1
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
May 12
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Dec 1
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Dec 10
| |||
Form 4
| +33.33% | 2K |
$5.96 | $11,920.00 | 8K |
Mar 6
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Dec 4
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Dec 20
| |||
Form 4
| +20.00% | 1K |
$8.23 | $8,228.00 | 6K |
Jun 14
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Dec 9
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Dec 7
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Dec 9
| |||
Form 4
|
∞
| 5K |
$1.44 | $7,200.00 | 5K |
Dec 1
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Apr 8
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||